TrialInternational journal of clinical oncology2024

Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations.

Nobuaki Matsubara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.